South Korea Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and Forecasts, 2026-2034

South Korea Cell and Gene Therapy Manufacturing QC Market Size

The South Korea Cell and Gene Therapy Manufacturing QC Market size was valued at USD 246 million in 2025 and is projected to grow from USD 281.42 million in 2026 to USD 825.60 million by 2034 at a CAGR of 14.4% during the forecast period 2026–2034.

South Korea is emerging as a critical player in this market, driven by the government's initiatives to boost biopharmaceuticals and regenerative medicine.

The country's well-established clinical trial infrastructure, advanced biotechnology capabilities, and strong research ecosystem position it as a key hub for innovative therapies. Moreover, with a growing number of South Korean biotech firms entering this space, the demand for QC solutions in manufacturing is set to grow substantially in the coming years.

Therapy Type Insights

Cell Therapy dominates the therapy type segment and is expected to augment at a CAGR of 25.1%. The cell therapy segment is witnessing significant growth in this region due to its focus on regenerative medicine, particularly stem cell therapies. Increased R&D investments, along with favorable government policies supporting clinical trials and commercialization, are driving the expansion of cell therapy applications across various diseases.

Request Customizationto receive a tailored report.

Scale Insights

Pre-commercial/ R&D Manufacturing dominates the scale segment and is estimated to grow at a CAGR of 27.6%. The pre-commercial/R&D manufacturing segment is expanding due to increased research and development efforts. Rising government funding, along with a surge in clinical trials for novel therapies, drives the demand for early-stage manufacturing and rigorous QC processes to meet regulatory standards.

Mode Insights

In-house Manufacturing is estimated to own the mode segment and is anticipated to expand at a CAGR of 26.8%. The in-house manufacturing mode is growing as South Korean biotech companies prefer greater control over the quality and production of cell and gene therapies. By establishing in-house QC capabilities, companies can ensure compliance with regulatory requirements, accelerate development timelines, and reduce reliance on third-party manufacturers, enhancing overall efficiency.

Speak to an Analystto discuss market opportunities.

Country Insights

South Korea is emerging as a key regional player in this market due to its advanced healthcare infrastructure and government initiatives supporting biotechnology. The country has established itself as a leader in clinical trials, with the Korean National Enterprise for Clinical Trials (KoNECT) facilitating collaborations between local institutions and global pharmaceutical firms. South Korea is also home to leading biopharma manufacturing companies such as Samsung Biologics and Celltrion, both of which are actively involved in cell and gene therapy production.

According to data from KoNECT, South Korea ranks among the top countries globally in terms of the number of clinical trials conducted, which is driving demand for stringent QC protocols. Additionally, the country has implemented policies to enhance the country's research ecosystem, such as tax breaks and subsidies for biotech startups, contributing to the growth of QC solutions. Furthermore, the country's biopharmaceutical exports are also on the rise, with an increasing focus on regenerative medicine and cell therapies, further driving the need for QC processes that meet global standards. These factors position South Korean cell and gene therapy manufacturing QC as a prominent area in the Asia Pacific region.

List of Key and Emerging Players in South Korea Cell and Gene Therapy Manufacturing QC Market